Ciprofloxacin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ciprofloxacin: From Bacterial Infections to Diffuse Scleroderma
One-Sentence Summary
Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic widely used for the treatment of bacterial infections across multiple organ systems. The TxGNN model predicts it may be effective for Diffuse Scleroderma, with 0 clinical trials and 2 publications currently supporting this direction. The mechanistic rationale is biologically plausible, but robust clinical evidence remains absent.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (broad-spectrum antibiotic; fluoroquinolone class) |
| Predicted New Indication | Diffuse Scleroderma |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L3 |
| Denmark Market Status | Not marketed (data gap — 0 licences recorded; may reflect incomplete regulatory data collection) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known information, ciprofloxacin is a fluoroquinolone antibiotic whose bactericidal activity is mediated through inhibition of bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and repair in susceptible organisms.
Beyond its antibacterial activity, ciprofloxacin has demonstrated antifibrotic properties in experimental and early clinical settings: it can inhibit human dermal fibroblast proliferation and collagen synthesis, and has been shown to suppress matrix metalloproteinase (MMP)-related pathways involved in extracellular matrix remodelling. Diffuse scleroderma (systemic sclerosis) is characterised by progressive fibrosis of the skin and internal organs driven by fibroblast overactivation and excessive collagen deposition — precisely the processes ciprofloxacin may attenuate.
An additional mechanistic pathway involves the gastrointestinal microbiome. Patients with systemic sclerosis frequently develop small intestinal bacterial overgrowth (SIBO), which amplifies systemic inflammatory burden and may accelerate fibrotic progression. Ciprofloxacin’s broad-spectrum antibacterial coverage can reduce SIBO-associated dysbiosis and thereby indirectly dampen the inflammatory signals that perpetuate fibrosis. Taken together, both direct antifibrotic and indirect microbiome-modulating mechanisms provide a biologically coherent rationale, though no large randomised controlled trial has yet validated this hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20507401 | 2010 | Small clinical study (likely pilot/RCT) | The Journal of Dermatology | Controlled, double-blind randomised study evaluating oral ciprofloxacin as an antifibrotic agent in scleroderma patients; assessed reduction in skin fibrosis severity |
| 7728404 | 1995 | Diagnostic/clinical study | British Journal of Rheumatology | Investigated SIBO in 24 systemic sclerosis patients using jejunal aspiration; reported treatment outcomes including antibiotic therapy, supporting indirect relevance of ciprofloxacin to scleroderma management |
Denmark Market Information
No marketing authorisations are currently recorded for ciprofloxacin in this dataset. This likely reflects an incomplete regulatory data collection step rather than actual absence from the Danish market, given that ciprofloxacin is a well-established generic antibiotic. Verification against the Laegemiddelstyrelsen product database and the EMA centralised authorisation register is recommended.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Note: Full Danish SmPC warnings, contraindications, and drug–drug interaction data were not retrieved in this Evidence Pack (classified as Blocking data gap DG001). Safety review cannot be completed until this information is obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence base consists of only two publications — one small pilot/randomised study and one diagnostic cohort study — with no registered clinical trials, placing this candidate at evidence level L3 (observational/small clinical study). While the antifibrotic and SIBO-modulating mechanisms are biologically plausible, the totality of evidence is insufficient to support clinical progression without further data.
To proceed, the following is needed:
- Regulatory data (Blocking): Obtain and review the full SmPC from Laegemiddelstyrelsen (Danish Medicines Agency) and any relevant EMA product information, including warnings, contraindications, and labelled drug interactions
- MOA data (High priority): Retrieve structured mechanism of action data from DrugBank (DB00537) to enable formal mechanistic-link scoring
- Full text retrieval: Obtain the complete publication for PMID 20507401 to confirm study design, sample size, primary endpoints, and outcome data
- Systematic literature search: Conduct a comprehensive search for additional preclinical and clinical evidence on ciprofloxacin in systemic sclerosis / scleroderma
- Clinical trial registration check: Search ClinicalTrials.gov, EudraCT (EU Clinical Trials Register), and WHO ICTRP with broader search terms (e.g., “scleroderma”, “systemic sclerosis”, “fibrosis”) to identify any ongoing or planned trials
- Safety monitoring plan: Before any clinical use, a risk–benefit assessment addressing fluoroquinolone class effects (tendinopathy, QT prolongation, peripheral neuropathy) in a chronic autoimmune disease population is required
This report is generated for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.